{
    "nctId": "NCT01388647",
    "briefTitle": "Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer",
    "officialTitle": "Phase I/II Study of Neoadjuvant Carboplatin, Eribulin Mesylate and Trastuzumab (ECH) for Operable HER2 Positive Breast Cancer",
    "overallStatus": "TERMINATED",
    "conditions": "HER-2 Positive Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 12,
    "primaryOutcomeMeasure": "Pathologic Response",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Written informed consent\n* Females; 18 years of age or greater\n* Histologically proven invasive breast cancer\n* American Joint Committee on Cancer (AJCC) clinical stage IIA - IIIB\n* Tumor size greater than 10 millimeters\n* HER2 positive\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Estrogen receptor (ER) positive or negative\n* Ejection fraction greater than or equal to lower limit of normal for the institution by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA)\n* Less than or equal to Grade 1 neuropathy according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0\n* Planned lumpectomy or mastectomy\n* Eligible for radiation therapy\n* No prior treatment for invasive breast cancer\n* Adequate organ system function per protocol as determined within 7 days prior to first dose of study treatment\n* Women of childbearing potential must have a negative pregnancy test within 7 days prior to the first dose of study treatment and must agree to use adequate contraception methods during study treatment and for a minimum of 6 months following trastuzumab discontinuation\n* Female subjects who are lactating should discontinue nursing prior to the first dose of study treatment and should refrain from nursing throughout the treatment period\n\nExclusion Criteria:\n\n* Fine needle cytology only without other histologic evidence of invasive breast cancer\n* Inflammatory breast cancer\n* AJCC clinical stage T1a-b breast cancer (primary tumor less than or equal to 10 millimeters)\n* Evidence of metastatic disease\n* HER2 negative\n* Ejection fraction less than lower limit of normal for the institution by ECHO or MUGA\n* Corrected QT interval greater than 480 milliseconds\n* Pre-existing cardiac dysfunction\n* Prior history of invasive cancer within the past 3 years\n* Synchronous bilateral breast cancer\n* Pre-existing CTCAE v4.0 Grade 2 or greater neuropathy\n* Hypersensitivity to halichondrin B or halichondrin B chemical derivative\n* History of severe allergic reactions to cisplatin or other platinum containing compounds, or mannitol\n* Mild, moderate, or severe hepatic impairment\n* Moderate or severe renal impairment\n* Hypokalemia or hypomagnesemia if it cannot be corrected prior to the first dose of study treatment\n* Organ allografts requiring immunosuppression\n* Known positive human immunodeficiency virus (HIV) status\n* Prior major surgery within 28 days prior to the first dose of study treatment and/or presence of any non-healing wound, fracture, or ulcer\n* Minor surgery or radiation therapy within 14 days prior to the first dose of study treatment\n* Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with subject's safety, provision of informed consent, or compliance to study procedures",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}